Search results
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 4 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
The Wall Street Journal· 3 days agoIf it succeeds in testing, it would escalate the race for even more potent drugs to target obesity....
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 4 days agoNo direct competitor of Pfizer has the Food and Drug Administration's approval for any DMD drugs. The only company...However, Sarepta is a much smaller...
Sun Pharma Prevails in Lipitor MDL on Class Certification, Summary Judgment | New Jersey Law Journal
Law.com· 5 days agoA group of Lipitor purchasers that included retailers, wholesalers, health insurance companies, and...
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Motley Fool via Yahoo Finance· 20 hours agoPfizer reported first-quarter sales that rose 11% year over year if we exclude Comirnaty and...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 3 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 3 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 3 days agoThe biotech group ranks No. 40 out of 197 industry groups that IBD tracks. Meanwhile, the pharma...
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The Motley Fool via AOL· 5 days agoBut the cost realignment plan and Pfizer's focus on its new drugs and programs -- including its...
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
Motley Fool via Yahoo Finance· 23 hours agoThat's phenomenal for a company of this size in almost any industry. And that's before we add that...
